{"id":"daridorexant","rwe":[{"pmid":"41879869","year":"2026","title":"Unveiling the binding mechanism of orexin 2 receptor antagonists with computational chemistry.","finding":"","journal":"Physical chemistry chemical physics : PCCP","studyType":"Clinical Study"},{"pmid":"41837408","year":"2026","title":"What place does daridorexant have in the treatment of Binge-Eating Disorder?","finding":"","journal":"Expert review of neurotherapeutics","studyType":"Clinical Study"},{"pmid":"41817674","year":"2026","title":"Daridorexant: exploring its role in the treatment of insomnia disorder.","finding":"","journal":"Expert review of neurotherapeutics","studyType":"Clinical Study"},{"pmid":"41719767","year":"2026","title":"Real-world findings of daridorexant in chronic insomnia: A pilot study on subjective and actigraphic sleep parameters.","finding":"","journal":"Sleep medicine","studyType":"Clinical Study"},{"pmid":"41700897","year":"2026","title":"Clinical toxicity of daridorexant: a retrospective analysis of poison centre data.","finding":"","journal":"Clinical toxicology (Philadelphia, Pa.)","studyType":"Clinical Study"}],"_fda":{"id":"10e24e38-5645-433d-a160-82f4ed5b6dfb","abuse":["9.2 Abuse Drug abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. The abuse potential of daridorexant was evaluated in preclinical models, recreational sedative drug users, and insomnia subjects. In a human abuse potential study conducted in 63 recreational sedative drug users, the effect of single-dose administration of QUVIVIQ [50 mg, 100 mg (two times the maximum recommended dose), and 150 mg (three times the maximum recommended dose)], zolpidem (30 mg), suvorexant (150 mg), and placebo on subjective rating of \"drug liking\" was evaluated. At the dose of 50 mg, QUVIVIQ showed significantly lower \"drug liking\" ratings than zolpidem (30 mg) and suvorexant (150 mg), but significantly higher than placebo. At doses of 100 mg (two times the maximum recommended dose) and 150 mg (three times the maximum recommended dose), QUVIVIQ showed similar \"drug liking\" ratings to zolpidem (30 mg) and suvorexant (150 mg). In placebo-controlled Phase 3 clinical studies in which 1232 subjects with insomnia were treated with QUVIVIQ for up to 12 months, there were no reports indicative of abuse liability. Because individuals with a history of abuse of or addiction to alcohol or other drugs may be at increased risk for abuse of or addiction to QUVIVIQ, follow such patients carefully."],"set_id":"3a2d1503-b816-40c9-9fac-7e03c5a3bcef","openfda":{"nui":["N0000191000","N0000190998"],"unii":["LMQ24G57E9"],"route":["ORAL"],"rxcui":["2591502","2591508","2599096","2599098"],"spl_id":["10e24e38-5645-433d-a160-82f4ed5b6dfb"],"brand_name":["QUVIVIQ"],"spl_set_id":["3a2d1503-b816-40c9-9fac-7e03c5a3bcef"],"package_ndc":["80491-7825-3","80491-7825-1","80491-7825-2","80491-7850-3","80491-7850-1","80491-7850-2"],"product_ndc":["80491-7825","80491-7850"],"generic_name":["DARIDOREXANT"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DARIDOREXANT"],"pharm_class_epc":["Orexin Receptor Antagonist [EPC]"],"pharm_class_moa":["Orexin Receptor Antagonists [MoA]"],"manufacturer_name":["Idorsia Pharmaceuticals Ltd"],"application_number":["NDA214985"],"is_original_packager":[true]},"version":"13","pregnancy":["8.1 Pregnancy Pregnancy Exposure Registry There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to QUVIVIQ during pregnancy. Pregnant women exposed to QUVIVIQ and healthcare providers are encouraged to call Idorsia Pharmaceuticals Ltd at 1-833-400-9611. Risk Summary There are no available data on QUVIVIQ use in pregnant women to evaluate for drug-associated risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of daridorexant to pregnant rats and rabbits during the period of organogenesis did not cause fetal toxicity or malformation at doses up to 8 and 10 times the maximum recommended human dose (MRHD) of 50 mg, respectively, based on AUC. Oral administration of daridorexant to pregnant and lactating rats did not cause any maternal or developmental toxicity at doses up to 9 times the MRHD, based on AUC (see Data ) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Daridorexant was administered orally to pregnant rats during the period of organogenesis at doses of 30, 100, and 300 mg/kg/day, which are approximately 1, 3, and 8 times the MRHD of 50 mg, respectively, based on AUC. Daridorexant did not cause any maternal or embryofetal toxicities or fetal malformation at doses up to 300 mg/kg/day. The NOAEL for maternal and fetal toxicity is 300 mg/kg/day, which is approximately 8 times the MRHD of 50 mg, based on AUC. Daridorexant was administered orally to pregnant rabbits during the period of organogenesis at doses of 30, 60, and 120 mg/kg/day, which are approximately 3, 4, and 10 times the MRHD of 50 mg, respectively, based on AUC. Daridorexant did not cause any fetal toxicity or malformation at doses up to 120 mg/kg/day. Daridorexant caused maternal toxicities of decreased weight gain and food consumption at the dose of 120 mg/kg/day. The NOAELs for maternal and fetal toxicity are 60 and 120 mg/kg/day, respectively, which are approximately 4 and 10 times the MRHD of 50 mg, respectively, based on AUC. Daridorexant was administered orally to pregnant rats during gestation and lactation at doses of 50, 100, and 300 mg/kg/day, which are approximately 1, 3, and 9 times the MRHD of 50 mg, respectively, based on AUC. Daridorexant did not cause any maternal or developmental toxicities at doses up to 300 mg/kg/day. The NOAEL for maternal and developmental toxicity is 300 mg/kg/day, which is approximately 9 times the MRHD of 50 mg, based on AUC."],"dependence":["9.3 Dependence Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms upon abrupt treatment discontinuation or a significant dose reduction of a drug. In animal studies and clinical trials evaluating physical dependence, chronic administration of daridorexant did not produce withdrawal signs or symptoms upon drug discontinuation. This suggests that daridorexant does not produce physical dependence."],"overdosage":["10 OVERDOSAGE There is limited clinical experience with QUVIVIQ overdose. In clinical pharmacology studies, healthy subjects were administered single doses of up to 200 mg (4 times the maximum recommended dose) of QUVIVIQ. The following adverse reactions were observed: somnolence, muscle weakness, cataplexy-like symptoms, sleep paralysis, disturbance in attention, fatigue, headache, and constipation. There is no specific antidote to an overdosage of QUVIVIQ. In the event of an overdose, general symptomatic and supportive medical care, along with immediate gastric lavage where appropriate, should be provided and patients should be carefully monitored. Dialysis is unlikely to be effective as daridorexant is highly protein bound. Consider contacting the Poison Help Line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations."],"description":["11 DESCRIPTION QUVIVIQ contains daridorexant, an orexin receptor antagonist, present as daridorexant hydrochloride salt. The chemical name of daridorexant hydrochloride is (S)-(2-(5-chloro-4-methyl-1 H -benzo[ d ]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2 H -1,2,3-triazol-2-yl)phenyl)methanone hydrochloride. The molecular formula is C 23 H 23 N 6 O 2 Cl * HCl. The molecular weight is 487.38 g/mol. The structural formula is: Daridorexant hydrochloride is a white to light yellowish powder that is very slightly soluble in water. QUVIVIQ tablets are intended for oral administration. Each film-coated tablet contains daridorexant 25 mg or 50 mg, equivalent to 27 mg or 54 mg of daridorexant hydrochloride, respectively. The inactive ingredients are croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, povidone, and silicon dioxide. In addition, the film coating contains the following inactive ingredients: glycerin, hypromellose, iron oxide black, iron oxide red, microcrystalline cellulose, talc, titanium dioxide, and, in the 50 mg tablet only, iron oxide yellow. Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied QUVIVIQ tablets are available as: 25 mg, light purple, arc-triangle shaped film-coated tablets debossed with \"25\" on one side, and \"i\" on the other side. NDC 80491-7825-3, bottle of 30 with child-resistant closure 50 mg: light orange, arc-triangle shaped film-coated tablets debossed with \"50\" on one side, and \"i\" on the other side. NDC 80491-7850-3, bottle of 30 with child-resistant closure 16.2 Storage and Handling Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]."],"spl_medguide":["MEDICATION GUIDE QUVIVIQ ® (cue-VIH-vick) (daridorexant) tablets, for oral use, CIV This Medication Guide has been approved by the U.S. Food and Drug Administration. IDRSQUMG09302024 Revised: 9/2024 What is the most important information I should know about QUVIVIQ? QUVIVIQ may cause serious side effects, including: Decreased awareness and alertness. The morning after you take QUVIVIQ, your ability to drive safely and think clearly may be decreased. You may also have sleepiness during the day. Sleepiness may increase your risk for falls. Do not take more QUVIVIQ than prescribed. Do not take QUVIVIQ unless you are able to stay in bed for a full night (at least 7 hours) before you must be active again. Take QUVIVIQ in the evening within 30 minutes before going to bed. See \" What are the possible side effects of QUVIVIQ? \" for more information about side effects. What is QUVIVIQ? QUVIVIQ is a prescription medicine for adults who have trouble falling asleep or staying asleep (insomnia). It is not known if QUVIVIQ is safe and effective for use in children. QUVIVIQ is a federally controlled substance (CIV) because it can be abused or lead to dependence. Keep QUVIVIQ in a safe place to prevent misuse and abuse. Selling or giving away QUVIVIQ may harm others and is against the law. Who should not take QUVIVIQ? Do not take QUVIVIQ: If you fall asleep often at unexpected times (narcolepsy). If you are allergic to daridorexant, or any ingredients in QUVIVIQ. See the end of this Medication Guide for a complete list of ingredients in QUVIVIQ. Before taking QUVIVIQ, tell your healthcare provider about all of your medical conditions, including if you: have a history of depression, mental illness, or suicidal thoughts or actions have a history of drug or alcohol abuse or addiction have a history of a sudden onset of muscle weakness (cataplexy) have a history of daytime sleepiness have lung or breathing problems, including sleep apnea have liver problems are pregnant or plan to become pregnant. It is not known if QUVIVIQ can harm your unborn baby. Pregnancy Registry : There is a pregnancy registry for women who are exposed to QUVIVIQ during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. For more information or to participate in the registry, call 1-833-400-9611. Talk with your healthcare provider about the risk to your unborn baby if you take QUVIVIQ during pregnancy. are breastfeeding or plan to breastfeed. QUVIVIQ passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with QUVIVIQ. Tell your healthcare provider about all of the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking QUVIVIQ with certain medicines can cause serious side effects. QUVIVIQ may affect the way other medicines work and other medicines may affect the way QUVIVIQ works. Do not take QUVIVIQ with other medicines that can make you sleepy unless your healthcare provider tells you to. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I take QUVIVIQ? Take QUVIVIQ exactly as your healthcare provider tells you to take it. Do not change your dose of QUVIVIQ without first talking to your healthcare provider. Take QUVIVIQ one time each night , within 30 minutes before going to bed. Only take QUVIVIQ when you can stay in bed for a full night (at least 7 hours). QUVIVIQ may take longer to work if you take it with or right after a meal. Call your healthcare provider if your insomnia (sleep problem) worsens or is not improved within 7 to 10 days. This may mean that there is another condition causing your sleep problem. If you take too much QUVIVIQ, call your healthcare provider, or contact your Poison Help Line at 1-800-222-1222, or go to the nearest hospital emergency room right away. What should I avoid while taking QUVIVIQ? Do not drink alcohol while taking QUVIVIQ. It can increase the effects of alcohol, which can be dangerous. You may still feel drowsy the next day after taking QUVIVIQ. Do not drive, operate heavy machinery, do anything dangerous, or do other activities that require clear thinking if you have taken QUVIVIQ as prescribed but do not feel fully awake, you have taken QUVIVIQ and have had less than a full night of sleep (at least 7 hours), or if you have taken more QUVIVIQ than prescribed by your healthcare provider. What are the possible side effects of QUVIVIQ? QUVIVIQ may cause serious side effects, including: See \" What is the most important information I should know about QUVIVIQ? \" Worsening depression and suicidal thoughts. Call your healthcare provider right away if you have any worsening depression or thoughts of suicide or dying. Temporary inability to move or talk (sleep paralysis) for up to several minutes, or hallucinations while you are going to sleep or waking up. Temporary weakness in your legs that can happen during the day or at night. Complex sleep behaviors such as sleepwalking, sleep driving, preparing and eating food, making phone calls, having sex, or doing other activities while not fully awake that you may not remember the next morning. Stop taking QUVIVIQ and call your healthcare provider right away if you experience a complex sleep behavior. The most common side effects of QUVIVIQ include headache and sleepiness or tiredness. These are not all of the possible side effects of QUVIVIQ. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store QUVIVIQ? Store QUVIVIQ at room temperature between 68°F to 77°F (20°C to 25°C). Keep QUVIVIQ and all medicines out of the reach of children. General information about the safe and effective use of QUVIVIQ. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use QUVIVIQ for a condition for which it was not prescribed. Do not give QUVIVIQ to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about QUVIVIQ that is written for health professionals. What are the ingredients in QUVIVIQ? Active ingredient : daridorexant hydrochloride Inactive ingredients : croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, povidone, and silicon dioxide. The tablet film coating contains: glycerin, hypromellose, iron oxide black, iron oxide red, microcrystalline cellulose, talc, titanium dioxide, and, in the 50 mg tablet only, iron oxide yellow. Distributed by: Idorsia Pharmaceuticals US Inc. One Radnor Corporate Center, Suite 101 100 Matsonford Rd Radnor, PA 19087 For more information go to QUVIVIQ.com or call 1-833-400-9611."],"geriatric_use":["8.5 Geriatric Use No dose adjustment is required in patients over the age of 65 years. Of the total number of subjects in the clinical studies of QUVIVIQ with insomnia (N = 1854), approximately 39% (N = 727) were ≥ 65 years and 5.9% (N = 110) were ≥ 75 years. The likelihood of somnolence and fatigue increased with patient age. Because QUVIVIQ can increase somnolence and drowsiness, patients, particularly the elderly, are at higher risk of falls [see Warnings and Precautions (5.1) ] ."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of QUVIVIQ have not been established in pediatric patients."],"effective_time":"20260226","clinical_studies":["14 CLINICAL STUDIES 14.1 Controlled Clinical Studies The efficacy of QUVIVIQ was evaluated in two multicenter, randomized, double-blind, placebo-controlled, parallel-group studies, Study 1 (NCT03545191) and Study 2 (NCT03575104). A total of 1854 patients with Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5 ® ) insomnia were randomized to receive QUVIVIQ or placebo once daily, in the evening, for 3 months. Study 1 randomized 930 subjects to QUVIVIQ 50 mg (N = 310), 25 mg (N = 310) or placebo (N = 310). Study 2 randomized 924 subjects to QUVIVIQ 25 mg (N = 309), 10 mg (N = 307), or placebo (N = 308). The 10 mg dose is not an approved dose. At the end of the 3-month treatment period, both studies included a 7-day placebo run-out period, after which patients could enter a 9-month, double-blind, placebo-controlled extension study (Study 3, NCT03679884). In Study 1, patients had a mean age of 55.4 years (range 18 to 88 years), with 39.1% of subjects ≥ 65 years of age, including 5.8% ≥ 75 years of age. Patients were identified as female or male and by US census-based racial and ethnic categories. The percentages of patients in the respective categories were: female sex (67.1%), White (90%), Black or African American (8%), Asian (1.0%), or Other race (< 1%). In Study 2, patients had a mean age of 56.7 years (range 19 to 85 years), with 39.3% of subjects ≥ 65 years of age, including 6.1% ≥ 75 years of age. Patients were identified as female or male and by US census-based racial and ethnic categories. The percentages of patients in the respective categories were: female sex (69.0%), White (88%), Black or African American (8%), Asian (4%), or Other race (< 1%). Primary efficacy endpoints for both studies were the change from baseline to Month 1 and Month 3 in Latency to Persistent Sleep (LPS) and Wake After Sleep Onset (WASO), measured objectively by polysomnography in a sleep laboratory. LPS is a measure of sleep induction and WASO is a measure of sleep maintenance. Secondary endpoint included in the statistical testing hierarchy with Type 1 error control was patient-reported Total Sleep Time (sTST), evaluated every morning at home using a validated Sleep Diary Questionnaire (SDQ). In Study 1, doses of 25 and 50 mg QUVIVIQ showed a statistically significant improvement vs placebo on polysomnography (LPS, WASO) and self-reported total sleep (sTST), at Month 1 and Month 3 (Table 4). In Study 2, QUVIVIQ 25 mg showed a statistically significant improvement vs placebo on WASO and sTST at Month 1 and Month 3 (Table 5). QUVIVIQ 10 mg did not show a statistically significant improvement on LPS, WASO, or sTST at Month 1 or Month 3. The efficacy of QUVIVIQ was similar across subgroups based on age, sex, race, and region. Table 4 Primary and Secondary Efficacy Results for Change from Baseline in Sleep Onset, Sleep Maintenance, and Subjective Total Sleep Time at Month 1 and Month 3 in Patients with Insomnia (Study 1) Treatment group/dose (N) Baseline Month 1 Month 3 Change from baseline Difference to placebo Change from baseline Difference to placebo mean (SD) mean (SD) LSM (95%CL) LSM (95%CL) mean (SD) LSM (95%CL) LSM (95%CL) CL = confidence limit; LPS = latency to persistent sleep; LSM = least squares mean; PSG = polysomnography; SD = standard deviation; sTST = subjective total sleep time; WASO = wake after sleep onset. WASO (wake after sleep onset, min): sleep maintenance, assessed by PSG 50 mg (310) 95 (38) 65 (35) -29 [-33, -25] -23 doses that were statistically significantly superior (p < 0.05) to placebo after controlling for multiple comparisons. [-28, -18] 65 (39) -29 [-33, -25] -18 [-24, -13] 25 mg (310) 98 (39) 77 (42) -18 [-22, -15] -12 [-17, -7] 73 (40) -23 [-27, -19] -12 [-17, -6] placebo (310) 103 (41) 92 (42) -6 [-10, -2] 87 (43) -11 [-15, -7] LPS (latency to persistent sleep, min): sleep onset, assessed by PSG 50 mg (310) 64 (37) 34 (27) -31 [-35, -28] -11 [-16, -7] 30 (23) -35 [-38, -31] -12 [-16, -7] 25 mg (310) 67 (39) 38 (32) -28 [-32, -25] -8 [-13, -4] 36 (34) -31 [-34, -27] -8 [-12, -3] placebo (310) 67 (40) 46 (36) -20 [-23, -17] 43 (34) -23 [-26, -20] sTST (subjective total sleep time, min): patient-reported 50 mg (310) 313 (58) 358 (74) 44 [38, 49] 22 [14, 30] 372 (79) 58 [51, 64] 20 [11, 29] 25 mg (310) 310 (60) 345 (66) 34 [29, 40] 13 [5, 20] 358 (72) 48 [41, 54] 10 [1, 19] placebo (310) 316 (53) 338 (65) 22 [16, 27] 354 (73) 38 [31, 44] Table 5 Primary and Secondary Efficacy Results for Change from Baseline in Sleep Onset, Sleep Maintenance, and Subjective Total Sleep Time at Month 1 and Month 3 in Patients with Insomnia (Study 2) Treatment group/dose (N) Baseline Month 1 Month 3 Change from baseline Difference to placebo Change from baseline Difference to placebo mean (SD) mean (SD) LSM (95%CL) LSM (95%CL) mean (SD) LSM (95%CL) LSM (95%CL) CL = confidence limit; LPS = latency to persistent sleep; LSM = least squares mean; PSG = polysomnography; SD = standard deviation; sTST = subjective total sleep time; WASO = wake after sleep onset. WASO (wake after sleep onset, min): sleep maintenance, assessed by PSG 25 mg (309) 106 (49) 80 (44) -24 [-28, -20] -12 doses that were statistically significantly superior (p < 0.05) to placebo after controlling for multiple comparisons. [-18, -6] 80 (49) -24 [-29, -19] -10 [-17, -4] placebo (308) 108 (49) 93 (50) -13 [-17, -8] 91 (47) -14 [-19, -9] LPS (latency to persistent sleep, min): sleep onset, assessed by PSG 25 mg (309) 69 (41) 42 (39) -26 [-31, -22] -6 [-12, -1] 39 (37) -29 [-33, -24] -9 [-15, -3] placebo (308) 72 (46) 50 (40) -20 [-24, -16] 49 (46) -20 [-24, -15] sTST (subjective total sleep time, min): patient-reported 25 mg (309) 308 (53) 353 (67) 44 [38, 49] 16 [8, 24] 365 (70) 56 [50, 63] 19 [10, 28] placebo (308) 308 (52) 336 (63) 28 [22, 33] 347 (65) 37 [31, 43] The effects of QUVIVIQ on LPS, WASO, and sTST were observed at Month 1 and were maintained through Month 3. The change from baseline of sTST by week in Study 1 is presented in Figure 4. Figure 4 Change from Baseline of sTST by Week (Study 1) Figure 4 14.2 Special Safety Studies Effects on Driving A randomized, double-blind, placebo- and active-controlled, four-period crossover study evaluated the effects of nighttime administration of QUVIVIQ on next-morning driving performance, using a driving simulator, 9 hours after dosing in 30 healthy elderly subjects (65–79 years, median age 70 years; 15 men, 15 women) and 30 healthy adult subjects (50–64 years, median age 58 years; 15 men, 15 women). The primary driving performance outcome measure was change in Standard Deviation of Lateral Position (SDLP). Testing was conducted after one night (initial dosing) and after four consecutive nights of treatment with QUVIVIQ 50 mg and 100 mg (two times the maximum recommended daily dose). Zopiclone 7.5 mg was used as an active comparator. For both doses, QUVIVIQ caused a statistically significant impairment in next-morning driving performance in adult or elderly subjects (compared with placebo) after the first dose. Although the mean effect on driving performance was not statistically significant (compared to placebo) after 4 consecutive nights of treatment with either dose of QUVIVIQ, driving ability was impaired in some subjects taking QUVIVIQ. Patients should be cautioned about the potential for next-morning driving impairment because there is individual variation in sensitivity to QUVIVIQ. Withdrawal of Therapy Withdrawal Symptoms In controlled efficacy and safety studies, withdrawal effects were assessed by the Tyrer Benzodiazepine Withdrawal Symptom Questionnaire following discontinuation of QUVIVIQ, and by adverse event reporting during a single-blind placebo run-out period. No evidence of withdrawal symptoms was observed upon treatment discontinuation. Loss of Treatment Effect After Discontinuation The loss of effect from stopping treatment with QUVIVIQ was assessed during the placebo run-out period after 3 months of treatment with QUVIVIQ in Study 1 and Study 2. After treatment discontinuation, in Study 1, patients previously treated with QUVIVIQ 50 mg experienced mean increases of 25 minutes in WASO, 16 minutes in LPS during the next night of sleep, and a mean decrease in sTST of 14 minutes per night over the next week, as compared to the last assessment on treatment. Following QUVIVIQ 25 mg discontinuation, a similar pattern was observed with mean increases in WASO of 19 minutes, 15 minutes in LPS, and a mean decrease in sTST of 7 minutes. Similar changes were observed with the 25 mg dose in Study 2. In both studies, patients who were on placebo and continued on placebo in the run-out period experienced minimal changes in WASO, LPS, or sTST. Middle of the Night Safety The effect of QUVIVIQ on middle of the night safety was evaluated in a randomized, placebo-controlled three-period crossover study in 18 healthy adult (< 65 years) and 18 healthy elderly (≥ 65 years) subjects. The ability to awaken in response to a sound stimulus, postural stability, and memory were assessed following a scheduled awakening 4 hours after administration of 25 or 50 mg QUVIVIQ, or placebo. The ability to awaken to sound in the middle of the night was assessed using an audiometer that delivered 1000 Hz tones starting at 35 dB and increasing to 100 dB to determine the Auditory Awakening Threshold (AAT). There was no significant difference between QUVIVIQ (25 mg or 50 mg) and placebo in AAT. Postural stability was measured by assessing body sway using a body sway meter approximately 5 minutes after awakening. Evening dosing of QUVIVIQ 25 mg and 50 mg resulted in respective increases in mean (95% confidence limit) cumulative body sway over 2 minutes of 37 mm [2 mm, 71 mm] and 66 mm [31 mm, 100 mm] at 4 hours post-dose compared to placebo. A visual verbal learning test (VVLT) of immediate and delayed recall was administered to assess memory after middle of the night awakening (4 hours post-dose) in subjects receiving QUVIVIQ 25 mg or 50 mg. QUVIVIQ was associated with worse performance on the VVLT compared to placebo."],"pharmacodynamics":["12.2 Pharmacodynamics Daridorexant binds to and inhibits the orexin receptors OX1R and OX2R (Ki = 0.47 and 0.93 nM, respectively). Cardiac Electrophysiology At a dose 4 times the maximum recommended dose, QUVIVIQ does not prolong the QTc interval to any clinically relevant extent. Alcohol Co-administration of a single 50 mg dose of QUVIVIQ with alcohol at a blood level of 0.6 g/L led to additive effects on impairment of psychomotor performance (postural stability and alertness). Daridorexant did not affect alcohol concentrations and alcohol did not affect daridorexant concentrations [see Warnings and Precautions (5.1 , 5.4) , Drug Interactions (7.1) ]. Citalopram No clinically significant effect on psychomotor performance was observed when 50 mg QUVIVIQ was co-administered with 20 mg citalopram in healthy subjects at steady state."],"pharmacokinetics":["12.3 Pharmacokinetics Daridorexant plasma exposure is dose proportional from 25 mg to 50 mg. The daridorexant pharmacokinetic profile is similar following multiple-dose and single-dose administration with no accumulation. Absorption Daridorexant reaches peak plasma concentrations within 1–2 hours (T max ). Daridorexant has an absolute bioavailability of 62%. Effect of food In healthy subjects, a high-fat and high-calorie meal delayed the T max by 1.3 hours and decreased the C max by 16%, but did not affect the total exposure (AUC). Distribution Daridorexant has a volume of distribution of 31 L. Daridorexant is 99.7% bound to plasma proteins. The blood to plasma ratio is 0.64. Elimination The terminal half-life of daridorexant is approximately 8 hours. Metabolism Daridorexant undergoes extensive metabolism and is primarily metabolized by CYP3A4 (89%). Other CYP enzymes individually contribute to less than 3% of metabolic clearance of daridorexant. Excretion The primary route of daridorexant excretion is via feces (approximately 57%), followed by urine (approximately 28%), primarily as metabolites. Trace amounts of parent drug were found in feces and urine. Specific Populations Age, sex, race (White, Black, Asian), body size, and mild to severe renal impairment (Cockcroft-Gault < 30 mL/min, not on dialysis) did not have a clinically significant effect on the pharmacokinetics of daridorexant. The effect of severe hepatic impairment (Child-Pugh score ≥ 10) on the pharmacokinetics of daridorexant has not been studied. Effects of hepatic impairment and renal impairment on the exposure to daridorexant are summarized in Figure 1. Figure 1 Effects of hepatic impairment and renal impairment on daridorexant PK Daridorexant dose: 25 mg. Data are GMRs and 90% CIs. Hepatic impairment PK variables are based on the unbound fraction of daridorexant. Reference = matched healthy subjects. AUC = area under the plasma concentration-time curve from zero to infinity; CI = confidence interval; C max = maximum plasma concentration; GMR = geometric mean ratio; PK = pharmacokinetics. Figure 1 Drug Interaction Studies The effects of other compounds on the exposure to daridorexant are summarized in Figure 2. The effects of daridorexant on the exposure to other compounds are summarized in Figure 3. Effect of Other Compounds on QUVIVIQ Figure 2 Effect of co-administered compounds on the PK of daridorexant Daridorexant 50 mg was administered with interacting drugs, except with diltiazem (25 mg daridorexant). Interacting drugs were administered in multiple-dose fashion, except famotidine (single dose) and alcohol (5 h infusion at 0.6 g/L). Based on PBPK analysis: Concomitant use of itraconazole (a strong CYP3A4 inhibitor) increased daridorexant AUC by more than 400%. Concomitant use of rifampin (a strong CYP3A4 inducer) decreased daridorexant AUC by more than 50%. Data are GMRs and 90% CIs. Some 90% CIs are too narrow to be shown. AUC = area under the plasma concentration-time curve; CI = confidence interval; C max = maximum plasma concentration; GMR = geometric mean ratio; SSRI = selective serotonin reuptake inhibitor. Figure 2 Effect of QUVIVIQ on Other Compounds Figure 3 Effect of daridorexant on the PK of other compounds AUC = area under the plasma concentration-time curve; BCRP = breast cancer resistance protein; CI = confidence interval; C max = maximum plasma concentration; CP = cytochrome P450 enzyme; P-gp = P-glycoprotein; SSRI = selective serotonin reuptake inhibitor. Figure 3"],"adverse_reactions":["6 ADVERSE REACTIONS The following are discussed in detail in other sections of the labeling: CNS-Depressant Effects and Daytime Impairment [see Warnings and Precautions (5.1) ] Worsening of Depression/Suicidal Ideation [see Warnings and Precautions (5.2) ] Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, and Cataplexy-like Symptoms [see Warnings and Precautions (5.3) ] Complex Sleep Behaviors [see Warnings and Precautions (5.4) ] Patients with Compromised Respiratory Function [see Warnings and Precautions (5.5) ] The most common adverse reactions (reported in ≥ 5% of patients treated with QUVIVIQ and at an incidence ≥ than placebo) were headache and somnolence or fatigue. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Idorsia Pharmaceuticals Ltd at toll-free phone 1-833-400-9611 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. The safety of QUVIVIQ was evaluated in three placebo-controlled clinical studies (two 3-month studies of identical design [Study 1 and Study 2], and a 9-month extension study [Study 3]). Study 1 evaluated 50 mg and 25 mg doses of QUVIVIQ, while Study 2 evaluated a 25 mg dose and a 10 mg dose of QUVIVIQ. The 10 mg dose is not an approved dose. A total of 1232 patients (including approximately 40% elderly patients [≥ 65 years old]), received QUVIVIQ 50 mg (N = 308); 25 mg (N = 618); or 10 mg (an unapproved dose) (N = 306). A total of 576 patients were treated with QUVIVIQ for at least 6 months and 331 for at least 12 months. Most Common Adverse Reactions The most common reported adverse reaction (in at least 5% of patients and greater than placebo) during double-blind treatment in Study 1 was headache. Table 1 shows adverse reactions that occurred in at least 2% of patients treated with QUVIVIQ and more frequently than in patients who received placebo in Study 1. Table 1 Adverse Reactions Reported in ≥ 2% of QUVIVIQ-treated Patients and Greater than in Placebo-treated Patients in a 3-Month Placebo-Controlled Study (Study 1) QUVIVIQ QUVIVIQ Placebo 25 mg 50 mg (N=310) (N=308) (N=309) % % % Nervous System Disorders Headache The following terms were combined: Headache includes: headache, tension headache, migraine, migraine with aura, head discomfort Somnolence or fatigue includes: somnolence, sedation, fatigue, hypersomnia, lethargy Dizziness includes: dizziness, vertigo, labyrinthitis Nausea includes: nausea, vomiting, procedural nausea 6 7 5 Somnolence or fatigue 6 5 4 Dizziness 2 3 2 Gastro-intestinal disorders Nausea 0 3 2 Other Adverse Reactions Observed During Clinical Trials (Study 1 and Study 2) Other adverse reactions of < 2% frequency but greater than placebo are shown below. The following do not include adverse reactions 1) for which a drug cause was remote, 2) that were so general as to be uninformative, or 3) that were not considered to have clinically significant implications. Sleep paralysis was reported in 0.5% and 0.3% of patients receiving QUVIVIQ 25 mg and 50 mg, respectively, compared to no reports for placebo. Hypnagogic and hypnopompic hallucinations were reported in 0.6% of patients receiving QUVIVIQ 25 mg compared to no cases with QUVIVIQ 50 mg or placebo. 6.2 Post-Marketing Experience The following adverse reactions have been identified during post-approval use of QUVIVIQ. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Psychiatric disorders : Nightmares or abnormal dreams Immune system disorders: Hypersensitivity (including angioedema, rash, urticaria)"],"contraindications":["4 CONTRAINDICATIONS QUVIVIQ is contraindicated: in patients with narcolepsy. in patients with a history of hypersensitivity to daridorexant or any components of QUVIVIQ. Angioedema with pharyngeal involvement has been reported [see Adverse Reactions (6.2) ] . Narcolepsy. ( 4 ) Known hypersensitivity to daridorexant or other components of QUVIVIQ. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Avoid concomitant use. ( 2.2 , 7.1 ) Moderate CYP3A4 inhibitors: Maximum recommended dose is 25 mg. ( 2.2 , 7.1 ) Moderate or Strong CYP3A4 inducers: Avoid concomitant use. ( 7.1 ) 7.1 Effects of Other Drugs on QUVIVIQ Table 2 describes clinically significant drug interactions where the concomitant use of other drugs affects QUVIVIQ. Table 2 Effects of Other Drugs on QUVIVIQ Strong or Moderate CYP3A4 Inhibitors Clinical Implications: Concomitant use with a strong or moderate CYP3A4 inhibitor increases exposure to daridorexant [see Clinical Pharmacology (12.3) ] , which may increase the risk of QUVIVIQ adverse reactions. Prevention or Management: The recommended dose of QUVIVIQ is 25 mg when used with a moderate CYP3A4 inhibitor [see Dosage and Administration (2.2) ] . Concomitant use of QUVIVIQ with a strong inhibitor of CYP3A4 is not recommended [see Dosage and Administration (2.2) ] . Strong and Moderate CYP3A4 Inducers Clinical Implications: Concomitant use with a strong or moderate CYP3A4 inducer decreases exposure to daridorexant [see Clinical Pharmacology (12.3) ] , which may reduce the efficacy of QUVIVIQ. Prevention or Management: Concomitant use of QUVIVIQ with a strong or moderate inducer of CYP3A4 is not recommended [see Dosage and Administration (2.2) ] . Alcohol and Other CNS Depressants Clinical Implications: Concomitant use of alcohol or other CNS depressants with QUVIVIQ may lead to additive impairment of psychomotor performance and risk of CNS depression [see Clinical Pharmacology (12.2) ] . Prevention or Management: Avoid alcohol consumption with QUVIVIQ [see Warnings and Precautions (5.1) ] . Use with caution in patients receiving CNS depressants. Consider dose adjustment of QUVIVIQ and/or the CNS depressant(s) if used concomitantly [see Warnings and Precautions (5.1) ] . 7.2 Effects of QUVIVIQ on Other Drugs Table 3 describes clinically significant drug interactions where the concomitant use of QUVIVIQ affects other drugs. Table 3 Effects of QUVIVIQ on Other Drugs CYP3A4 Substrates Clinical Implications: Concomitant use of QUVIVIQ with CYP3A4 substrates increases the exposure to CYP3A4 substrate [see Clinical Pharmacology (12.3) ] . Prevention or Management: Use with caution in patients receiving CYP3A4 substrates with narrow therapeutic index. P-gp Substrates Clinical Implications: Concomitant use of QUVIVIQ with P-gp substrates increases the exposure to P-gp substrate [see Clinical Pharmacology (12.3) ] . Prevention or Management: Use with caution in patients receiving P-gp substrates with a narrow therapeutic index."],"spl_medguide_table":["
MEDICATION GUIDE QUVIVIQ® (cue-VIH-vick) (daridorexant) tablets, for oral use, CIV
This Medication Guide has been approved by the U.S. Food and Drug Administration. IDRSQUMG09302024Revised: 9/2024
What is the most important information I should know about QUVIVIQ? QUVIVIQ may cause serious side effects, including:Decreased awareness and alertness. The morning after you take QUVIVIQ, your ability to drive safely and think clearly may be decreased. You may also have sleepiness during the day. Sleepiness may increase your risk for falls.Do not take more QUVIVIQ than prescribed.Do not take QUVIVIQ unless you are able to stay in bed for a full night (at least 7 hours) before you must be active again.Take QUVIVIQ in the evening within 30 minutes before going to bed.See "What are the possible side effects of QUVIVIQ?" for more information about side effects.
What is QUVIVIQ?QUVIVIQ is a prescription medicine for adults who have trouble falling asleep or staying asleep (insomnia).It is not known if QUVIVIQ is safe and effective for use in children.QUVIVIQ is a federally controlled substance (CIV) because it can be abused or lead to dependence. Keep QUVIVIQ in a safe place to prevent misuse and abuse. Selling or giving away QUVIVIQ may harm others and is against the law.
Who should not take QUVIVIQ? Do not take QUVIVIQ:If you fall asleep often at unexpected times (narcolepsy).If you are allergic to daridorexant, or any ingredients in QUVIVIQ. See the end of this Medication Guide for a complete list of ingredients in QUVIVIQ.
Before taking QUVIVIQ, tell your healthcare provider about all of your medical conditions, including if you:have a history of depression, mental illness, or suicidal thoughts or actionshave a history of drug or alcohol abuse or addictionhave a history of a sudden onset of muscle weakness (cataplexy)have a history of daytime sleepinesshave lung or breathing problems, including sleep apneahave liver problemsare pregnant or plan to become pregnant. It is not known if QUVIVIQ can harm your unborn baby.Pregnancy Registry: There is a pregnancy registry for women who are exposed to QUVIVIQ during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. For more information or to participate in the registry, call 1-833-400-9611. Talk with your healthcare provider about the risk to your unborn baby if you take QUVIVIQ during pregnancy.are breastfeeding or plan to breastfeed. QUVIVIQ passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with QUVIVIQ.Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking QUVIVIQ with certain medicines can cause serious side effects. QUVIVIQ may affect the way other medicines work and other medicines may affect the way QUVIVIQ works. Do not take QUVIVIQ with other medicines that can make you sleepy unless your healthcare provider tells you to. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
How should I take QUVIVIQ?Take QUVIVIQ exactly as your healthcare provider tells you to take it.Do not change your dose of QUVIVIQ without first talking to your healthcare provider.Take QUVIVIQ one time each night, within 30 minutes before going to bed.Only take QUVIVIQ when you can stay in bed for a full night (at least 7 hours).QUVIVIQ may take longer to work if you take it with or right after a meal.Call your healthcare provider if your insomnia (sleep problem) worsens or is not improved within 7 to 10 days. This may mean that there is another condition causing your sleep problem.If you take too much QUVIVIQ, call your healthcare provider, or contact your Poison Help Line at 1-800-222-1222, or go to the nearest hospital emergency room right away.
What should I avoid while taking QUVIVIQ?Do not drink alcohol while taking QUVIVIQ. It can increase the effects of alcohol, which can be dangerous.You may still feel drowsy the next day after taking QUVIVIQ.Do not drive, operate heavy machinery, do anything dangerous, or do other activities that require clear thinking if you have taken QUVIVIQ as prescribed but do not feel fully awake, you have taken QUVIVIQ and have had less than a full night of sleep (at least 7 hours), or if you have taken more QUVIVIQ than prescribed by your healthcare provider.
What are the possible side effects of QUVIVIQ? QUVIVIQ may cause serious side effects, including:See "What is the most important information I should know about QUVIVIQ?"Worsening depression and suicidal thoughts. Call your healthcare provider right away if you have any worsening depression or thoughts of suicide or dying.Temporary inability to move or talk (sleep paralysis) for up to several minutes, or hallucinations while you are going to sleep or waking up. Temporary weakness in your legs that can happen during the day or at night.Complex sleep behaviors such as sleepwalking, sleep driving, preparing and eating food, making phone calls, having sex, or doing other activities while not fully awake that you may not remember the next morning. Stop taking QUVIVIQ and call your healthcare provider right away if you experience a complex sleep behavior.The most common side effects of QUVIVIQ include headache and sleepiness or tiredness. These are not all of the possible side effects of QUVIVIQ. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store QUVIVIQ?Store QUVIVIQ at room temperature between 68°F to 77°F (20°C to 25°C).Keep QUVIVIQ and all medicines out of the reach of children.
General information about the safe and effective use of QUVIVIQ. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use QUVIVIQ for a condition for which it was not prescribed. Do not give QUVIVIQ to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about QUVIVIQ that is written for health professionals.
What are the ingredients in QUVIVIQ? Active ingredient: daridorexant hydrochloride Inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, povidone, and silicon dioxide. The tablet film coating contains: glycerin, hypromellose, iron oxide black, iron oxide red, microcrystalline cellulose, talc, titanium dioxide, and, in the 50 mg tablet only, iron oxide yellow.
Distributed by: Idorsia Pharmaceuticals US Inc. One Radnor Corporate Center, Suite 101 100 Matsonford Rd Radnor, PA 19087 For more information go to QUVIVIQ.com or call 1-833-400-9611.
"],"mechanism_of_action":["12.1 Mechanism of Action The mechanism of action of daridorexant in the treatment of insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system plays a role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive."],"controlled_substance":["9.1 Controlled Substance QUVIVIQ contains daridorexant, a Schedule IV controlled substance."],"recent_major_changes":["Contraindications ( 4 ) 10/2023 Warnings and Precautions ( 5.5 ) 9/2024"],"storage_and_handling":["16.2 Storage and Handling Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action of daridorexant in the treatment of insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system plays a role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive. 12.2 Pharmacodynamics Daridorexant binds to and inhibits the orexin receptors OX1R and OX2R (Ki = 0.47 and 0.93 nM, respectively). Cardiac Electrophysiology At a dose 4 times the maximum recommended dose, QUVIVIQ does not prolong the QTc interval to any clinically relevant extent. Alcohol Co-administration of a single 50 mg dose of QUVIVIQ with alcohol at a blood level of 0.6 g/L led to additive effects on impairment of psychomotor performance (postural stability and alertness). Daridorexant did not affect alcohol concentrations and alcohol did not affect daridorexant concentrations [see Warnings and Precautions (5.1 , 5.4) , Drug Interactions (7.1) ]. Citalopram No clinically significant effect on psychomotor performance was observed when 50 mg QUVIVIQ was co-administered with 20 mg citalopram in healthy subjects at steady state. 12.3 Pharmacokinetics Daridorexant plasma exposure is dose proportional from 25 mg to 50 mg. The daridorexant pharmacokinetic profile is similar following multiple-dose and single-dose administration with no accumulation. Absorption Daridorexant reaches peak plasma concentrations within 1–2 hours (T max ). Daridorexant has an absolute bioavailability of 62%. Effect of food In healthy subjects, a high-fat and high-calorie meal delayed the T max by 1.3 hours and decreased the C max by 16%, but did not affect the total exposure (AUC). Distribution Daridorexant has a volume of distribution of 31 L. Daridorexant is 99.7% bound to plasma proteins. The blood to plasma ratio is 0.64. Elimination The terminal half-life of daridorexant is approximately 8 hours. Metabolism Daridorexant undergoes extensive metabolism and is primarily metabolized by CYP3A4 (89%). Other CYP enzymes individually contribute to less than 3% of metabolic clearance of daridorexant. Excretion The primary route of daridorexant excretion is via feces (approximately 57%), followed by urine (approximately 28%), primarily as metabolites. Trace amounts of parent drug were found in feces and urine. Specific Populations Age, sex, race (White, Black, Asian), body size, and mild to severe renal impairment (Cockcroft-Gault < 30 mL/min, not on dialysis) did not have a clinically significant effect on the pharmacokinetics of daridorexant. The effect of severe hepatic impairment (Child-Pugh score ≥ 10) on the pharmacokinetics of daridorexant has not been studied. Effects of hepatic impairment and renal impairment on the exposure to daridorexant are summarized in Figure 1. Figure 1 Effects of hepatic impairment and renal impairment on daridorexant PK Daridorexant dose: 25 mg. Data are GMRs and 90% CIs. Hepatic impairment PK variables are based on the unbound fraction of daridorexant. Reference = matched healthy subjects. AUC = area under the plasma concentration-time curve from zero to infinity; CI = confidence interval; C max = maximum plasma concentration; GMR = geometric mean ratio; PK = pharmacokinetics. Figure 1 Drug Interaction Studies The effects of other compounds on the exposure to daridorexant are summarized in Figure 2. The effects of daridorexant on the exposure to other compounds are summarized in Figure 3. Effect of Other Compounds on QUVIVIQ Figure 2 Effect of co-administered compounds on the PK of daridorexant Daridorexant 50 mg was administered with interacting drugs, except with diltiazem (25 mg daridorexant). Interacting drugs were administered in multiple-dose fashion, except famotidine (single dose) and alcohol (5 h infusion at 0.6 g/L). Based on PBPK analysis: Concomitant use of itraconazole (a strong CYP3A4 inhibitor) increased daridorexant AUC by more than 400%. Concomitant use of rifampin (a strong CYP3A4 inducer) decreased daridorexant AUC by more than 50%. Data are GMRs and 90% CIs. Some 90% CIs are too narrow to be shown. AUC = area under the plasma concentration-time curve; CI = confidence interval; C max = maximum plasma concentration; GMR = geometric mean ratio; SSRI = selective serotonin reuptake inhibitor. Figure 2 Effect of QUVIVIQ on Other Compounds Figure 3 Effect of daridorexant on the PK of other compounds AUC = area under the plasma concentration-time curve; BCRP = breast cancer resistance protein; CI = confidence interval; C max = maximum plasma concentration; CP = cytochrome P450 enzyme; P-gp = P-glycoprotein; SSRI = selective serotonin reuptake inhibitor. Figure 3"],"indications_and_usage":["1 INDICATIONS AND USAGE QUVIVIQ is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see Clinical Studies (14.1) ] . QUVIVIQ is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. Risk increases when used with other central nervous system (CNS) depressants. For patients taking QUVIVIQ, caution against next-day driving and other activities requiring complete mental alertness. ( 5.1 ) Worsening of Depression/Suicidal Ideation: Worsening of depression or suicidal thinking may occur. ( 5.2 ) Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, and Cataplexy-like Symptoms: May occur with use of QUVIVIQ. ( 5.3 ) Complex Sleep Behaviors: Behaviors including sleepwalking, sleep driving, and engaging in other activities while not fully awake may occur. Discontinue immediately if complex sleep behavior occurs. ( 5.4 ) Compromised Respiratory Function: Effect on respiratory function should be considered. ( 5.5 , 8.7 ) Need to Evaluate for Co-morbid Diagnoses: Reevaluate if insomnia persists after 7 to 10 days. ( 5.6 ) 5.1 CNS-Depressant Effects and Daytime Impairment QUVIVIQ is a central nervous system (CNS) depressant that can impair daytime wakefulness even when used as prescribed. CNS-depressant effects may persist in some patients for up to several days after discontinuing QUVIVIQ. Prescribers should advise patients about the potential for next-day somnolence. Driving ability was impaired in some subjects taking QUVIVIQ 50 mg [see Clinical Studies (14.2) ] . The risk of daytime impairment is increased if QUVIVIQ is taken with less than a full night of sleep remaining or if a higher than recommended dose is taken [see Dosage and Administration (2.1) ] . If QUVIVIQ is taken in these circumstances, caution patients against driving and other activities requiring complete mental alertness. Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. Dosage adjustments of QUVIVIQ and of concomitant CNS depressants may be necessary when administered together because of potentially additive effects. The use of QUVIVIQ with other drugs to treat insomnia is not recommended . Advise patients not to consume alcohol in combination with QUVIVIQ because co-administration of QUVIVIQ with alcohol resulted in additive effects on psychomotor performance [see Drug Interactions (7.1) ]. Because QUVIVIQ can cause drowsiness, patients, particularly the elderly, are at a higher risk of falls. 5.2 Worsening of Depression/Suicidal Ideation Patients with psychiatric disorders, including insomnia, are at increased risk of suicide. In primarily depressed patients treated with hypnotics, worsening of depression and suicidal thoughts and actions (including completed suicides) have been reported. As with other hypnotics, QUVIVIQ should be administered with caution in patients exhibiting symptoms of depression. Monitoring of suicide risk and protective measures may be required. 5.3 Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, and Cataplexy-like Symptoms Sleep paralysis, an inability to move or speak for up to several minutes during sleep-wake transitions, and hypnagogic/hypnopompic hallucinations, including vivid and disturbing perceptions, can occur with the use of QUVIVIQ [see Adverse Reactions (6.1) ] . Prescribers should explain the nature of these events to patients when prescribing QUVIVIQ. Symptoms similar to mild cataplexy have been reported with orexin receptor antagonists. Such symptoms can include periods of leg weakness lasting from seconds to a few minutes, can occur either at night or during the day, and may not be associated with an identified triggering event (e.g., laughter or surprise). 5.4 Complex Sleep Behaviors Complex sleep behaviors, including sleepwalking, sleep driving, and engaging in other activities while not fully awake (e.g., preparing and eating food, making phone calls, having sex), have been reported to occur with the use of hypnotics, including orexin receptor antagonists such as QUVIVIQ. These events can occur in hypnotic-naïve as well as in hypnotic-experienced persons. Patients usually do not remember these events. Complex sleep behaviors may occur following the first or any subsequent use of hypnotics, such as QUVIVIQ, with or without the concomitant use of alcohol and other CNS depressants [see Drug Interactions (7.1) ]. Discontinue QUVIVIQ immediately if a patient experiences a complex sleep behavior. 5.5 Patients with Compromised Respiratory Function QUVIVIQ has been studied in mild to severe OSA not using CPAP, and in patients with moderate COPD. The effects of QUVIVIQ on respiratory function should be considered if prescribed to patients with compromised respiratory function. QUVIVIQ has not been studied in patients with mild or severe COPD [see Use in Specific Populations (8.7) ]. 5.6 Need to Evaluate for Co-morbid Diagnoses Because sleep disturbances may be the presenting manifestation of a medical and/or psychiatric disorder, treatment of insomnia should be initiated only after careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. Worsening of insomnia or the emergence of new cognitive or behavioral abnormalities may be the result of an unrecognized underlying psychiatric or medical disorder and can emerge during the course of treatment with sleep-promoting drugs such as QUVIVIQ."],"clinical_studies_table":["
Table 4 Primary and Secondary Efficacy Results for Change from Baseline in Sleep Onset, Sleep Maintenance, and Subjective Total Sleep Time at Month 1 and Month 3 in Patients with Insomnia (Study 1)
Treatment group/dose (N)BaselineMonth 1Month 3
Change from baselineDifference to placeboChange from baselineDifference to placebo
mean (SD)mean (SD)LSM (95%CL)LSM (95%CL)mean (SD)LSM (95%CL)LSM (95%CL)
CL = confidence limit; LPS = latency to persistent sleep; LSM = least squares mean; PSG = polysomnography; SD = standard deviation; sTST = subjective total sleep time; WASO = wake after sleep onset.
WASO (wake after sleep onset, min): sleep maintenance, assessed by PSG
50 mg (310)95 (38)65 (35)-29 [-33, -25]-23doses that were statistically significantly superior (p < 0.05) to placebo after controlling for multiple comparisons. [-28, -18]65 (39)-29 [-33, -25]-18 [-24, -13]
25 mg (310)98 (39)77 (42)-18 [-22, -15]-12 [-17, -7]73 (40)-23 [-27, -19]-12 [-17, -6]
placebo (310)103 (41)92 (42)-6 [-10, -2]87 (43)-11 [-15, -7]
LPS (latency to persistent sleep, min): sleep onset, assessed by PSG
50 mg (310)64 (37)34 (27)-31 [-35, -28]-11 [-16, -7]30 (23)-35 [-38, -31]-12 [-16, -7]
25 mg (310)67 (39)38 (32)-28 [-32, -25]-8 [-13, -4]36 (34)-31 [-34, -27]-8 [-12, -3]
placebo (310)67 (40)46 (36)-20 [-23, -17]43 (34)-23 [-26, -20]
sTST (subjective total sleep time, min): patient-reported
50 mg (310)313 (58)358 (74)44 [38, 49]22 [14, 30]372 (79)58 [51, 64]20 [11, 29]
25 mg (310)310 (60)345 (66)34 [29, 40]13 [5, 20]358 (72)48 [41, 54]10 [1, 19]
placebo (310)316 (53)338 (65)22 [16, 27]354 (73)38 [31, 44]
","
Table 5 Primary and Secondary Efficacy Results for Change from Baseline in Sleep Onset, Sleep Maintenance, and Subjective Total Sleep Time at Month 1 and Month 3 in Patients with Insomnia (Study 2)
Treatment group/dose (N)BaselineMonth 1Month 3
Change from baselineDifference to placeboChange from baselineDifference to placebo
mean (SD)mean (SD)LSM (95%CL)LSM (95%CL)mean (SD)LSM (95%CL)LSM (95%CL)
CL = confidence limit; LPS = latency to persistent sleep; LSM = least squares mean; PSG = polysomnography; SD = standard deviation; sTST = subjective total sleep time; WASO = wake after sleep onset.
WASO (wake after sleep onset, min): sleep maintenance, assessed by PSG
25 mg (309)106 (49)80 (44)-24 [-28, -20]-12doses that were statistically significantly superior (p < 0.05) to placebo after controlling for multiple comparisons. [-18, -6]80 (49)-24 [-29, -19]-10 [-17, -4]
placebo (308)108 (49)93 (50)-13 [-17, -8]91 (47)-14 [-19, -9]
LPS (latency to persistent sleep, min): sleep onset, assessed by PSG
25 mg (309)69 (41)42 (39)-26 [-31, -22]-6 [-12, -1]39 (37)-29 [-33, -24]-9 [-15, -3]
placebo (308)72 (46)50 (40)-20 [-24, -16]49 (46)-20 [-24, -15]
sTST (subjective total sleep time, min): patient-reported
25 mg (309)308 (53)353 (67)44 [38, 49]16 [8, 24]365 (70)56 [50, 63]19 [10, 28]
placebo (308)308 (52)336 (63)28 [22, 33]347 (65)37 [31, 43]
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Daridorexant did not increase the incidence of tumors in rats treated for 2 years at oral doses of 15, 50, and 150 mg/kg/day. The high dose of 150 mg/kg/day is approximately 4 times the MRHD of 50 mg, based on AUC. Daridorexant did not increase the incidence of tumors in Tg.rasH2 mice treated for 26 weeks at oral doses of 100, 300, and 1000 mg/kg/day in males or 100, 200, and 1000 mg/kg/day in females. Mutagenesis Daridorexant was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay or in the in vitro mammalian chromosome aberration assay in human lymphocytes and was not clastogenic in the in vivo rat micronucleus assay. Impairment of Fertility Daridorexant was orally administered to female rats at doses of 30, 100, and 300 mg/kg/day prior to and throughout mating and continuing to gestation Day 6. These doses are approximately 0.5, 3, and 9 times the MRHD of 50 mg, based on AUC. Daridorexant increased pre-implantation loss and decreased implantation sites without affecting mating or fertility at 300 mg/kg/day. The NOAEL for female fertility is 100 mg/kg/day, which is approximately 3 times the MRHD of 50 mg, based on AUC. Daridorexant did not affect fertility when orally administered to male rats at doses of 50, 150, and 450 mg/kg/day prior to and throughout mating. These doses are approximately 1, 3, and 7 times the MRHD of 50 mg, based on AUC. 13.2 Animal Toxicology and/or Pharmacology In dogs, daily oral administration of daridorexant at ≥ 30 mg/kg/day resulted in behavior characteristic of cataplexy when presented with positive stimulation. The no-observed-effect level (NOEL) for cataplexy is 20 mg/kg/day, which is approximately 3 times the MRHD of 50 mg, based on C max and AUC."],"adverse_reactions_table":["
Table 1 Adverse Reactions Reported in ≥ 2% of QUVIVIQ-treated Patients and Greater than in Placebo-treated Patients in a 3-Month Placebo-Controlled Study (Study 1)
QUVIVIQQUVIVIQPlacebo
25 mg50 mg
(N=310)(N=308)(N=309)
%%%
Nervous System Disorders
HeadacheThe following terms were combined: Headache includes: headache, tension headache, migraine, migraine with aura, head discomfort Somnolence or fatigue includes: somnolence, sedation, fatigue, hypersomnia, lethargy Dizziness includes: dizziness, vertigo, labyrinthitis Nausea includes: nausea, vomiting, procedural nausea 675
Somnolence or fatigue654
Dizziness232
Gastro-intestinal disorders
Nausea032
"],"drug_interactions_table":["
Table 2 Effects of Other Drugs on QUVIVIQ
Strong or Moderate CYP3A4 Inhibitors
Clinical Implications:Concomitant use with a strong or moderate CYP3A4 inhibitor increases exposure to daridorexant [see Clinical Pharmacology (12.3)], which may increase the risk of QUVIVIQ adverse reactions.
Prevention or Management:The recommended dose of QUVIVIQ is 25 mg when used with a moderate CYP3A4 inhibitor [see Dosage and Administration (2.2)]. Concomitant use of QUVIVIQ with a strong inhibitor of CYP3A4 is not recommended [see Dosage and Administration (2.2)].
Strong and Moderate CYP3A4 Inducers
Clinical Implications:Concomitant use with a strong or moderate CYP3A4 inducer decreases exposure to daridorexant [see Clinical Pharmacology (12.3)], which may reduce the efficacy of QUVIVIQ.
Prevention or Management:Concomitant use of QUVIVIQ with a strong or moderate inducer of CYP3A4 is not recommended [see Dosage and Administration (2.2)].
Alcohol and Other CNS Depressants
Clinical Implications:Concomitant use of alcohol or other CNS depressants with QUVIVIQ may lead to additive impairment of psychomotor performance and risk of CNS depression [see Clinical Pharmacology (12.2)].
Prevention or Management:Avoid alcohol consumption with QUVIVIQ [see Warnings and Precautions (5.1)]. Use with caution in patients receiving CNS depressants. Consider dose adjustment of QUVIVIQ and/or the CNS depressant(s) if used concomitantly [see Warnings and Precautions (5.1)].
","
Table 3 Effects of QUVIVIQ on Other Drugs
CYP3A4 Substrates
Clinical Implications:Concomitant use of QUVIVIQ with CYP3A4 substrates increases the exposure to CYP3A4 substrate [see Clinical Pharmacology (12.3)].
Prevention or Management:Use with caution in patients receiving CYP3A4 substrates with narrow therapeutic index.
P-gp Substrates
Clinical Implications:Concomitant use of QUVIVIQ with P-gp substrates increases the exposure to P-gp substrate [see Clinical Pharmacology (12.3)].
Prevention or Management:Use with caution in patients receiving P-gp substrates with a narrow therapeutic index.
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Administration Instructions Advise patients to take QUVIVIQ only in the evening within 30 minutes before going to bed and only if they can stay in bed for a full night (at least 7 hours) before being active again [see Dosage and Administration (2.1) ] . Advise patients that the effect of QUVIVIQ may be delayed if taken with or soon after a meal [see Dosage and Administration (2.1) , Clinical Pharmacology (12.3) ] . CNS-Depressant Effects and Daytime Impairment Advise patients that QUVIVIQ can impair daytime wakefulness even when used as prescribed. The risk of daytime impairment is increased if QUVIVIQ is taken with less than a full night of sleep remaining or if a higher than recommended dose is taken. If QUVIVIQ is taken in these circumstances, caution patients against driving and other activities requiring complete mental alertness. Advise patients that increased drowsiness may increase the risk of falls in some patients [see Warnings and Precautions (5.1) , Clinical Studies (14.2) ] . Worsening of Depression/Suicidal Ideation Tell patients to report any worsening of depression or suicidal thoughts immediately [see Warnings and Precautions (5.2) ] . Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, and Cataplexy-Like Symptoms Advise patients and their families that QUVIVIQ may cause sleep paralysis, which is an inability to move or speak for several minutes during sleep-wake transitions and hypnagogic/hypnopompic hallucinations, including vivid and disturbing perceptions. Symptoms similar to mild cataplexy have occurred with orexin receptor antagonists [see Warnings and Precautions (5.3) ] . Complex Sleep Behaviors Instruct patients and their families that hypnotics may cause complex sleep behaviors, including sleepwalking, sleep driving, preparing and eating food, making phone calls, or having sex while not being fully awake. Tell patients to discontinue QUVIVIQ and notify their healthcare provider immediately if they develop any of these symptoms [see Warnings and Precautions (5.4) ]. Concomitant Medications Ask patients about alcohol consumption, medicines they are taking, and drugs they may be taking without a prescription. Advise patients to avoid consuming alcohol with QUVIVIQ [see Warnings and Precautions (5.1) , Drug Interactions (7.1) , Clinical Pharmacology (12.2) ] . Pregnancy Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to QUVIVIQ during pregnancy [see Use in Specific Populations (8.1) ]. Tolerance, Abuse, and Dependence Tell patients not to increase the dose of QUVIVIQ on their own, and to inform you if they believe the drug \"does not work\" [see Drug Abuse and Dependence (9) ] ."],"spl_unclassified_section":["Distributed by: Idorsia Pharmaceuticals US Inc. One Radnor Corporate Center, Suite 101 100 Matsonford Rd Radnor, PA 19087 IDRSQUPI09302024 Patent: www.idorsia.com/patents"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION The recommended dosage is 25 mg to 50 mg once per night, taken orally within 30 minutes before going to bed, with at least 7 hours remaining prior to planned awakening. ( 2.1 ) Time to sleep onset may be delayed if taken with or soon after a meal. ( 2.1 ) Hepatic Impairment: ( 2.3 ) Moderate hepatic impairment: Maximum recommended dosage is 25 mg no more than once per night. Severe hepatic impairment: Not recommended. 2.1 Recommended Dosage The recommended dosage range is 25 mg to 50 mg of QUVIVIQ taken orally no more than once per night within 30 minutes of going to bed (with at least 7 hours remaining prior to planned awakening). Time to sleep onset may be delayed if taken with or soon after a meal [see Clinical Pharmacology (12.3) ] . 2.2 Dosage Recommendations for Concomitant Use with CYP3A4 Inhibitors or CYP3A4 Inducers Co-administration with Strong CYP3A4 Inhibitors Avoid concomitant use of QUVIVIQ with strong inhibitors of CYP3A4 [see Drug Interactions (7.1) , Clinical Pharmacology (12.3) ] . Co-administration with Moderate CYP3A4 Inhibitors The recommended dosage of QUVIVIQ is 25 mg no more than once per night when used with moderate inhibitors of CYP3A4 [see Drug Interactions (7.1) , Clinical Pharmacology (12.3) ] . Co-administration with Strong or Moderate CYP3A4 Inducers Avoid concomitant use of QUVIVIQ with strong or moderate CYP3A4 inducers [see Drug Interactions (7.1) ] . 2.3 Dosage Recommendations for Patients with Hepatic Impairment The maximum recommended dosage in patients with moderate hepatic impairment (Child-Pugh score 7–9) is 25 mg of QUVIVIQ no more than once per night [see Use in Specific Populations (8.6) , Clinical Pharmacology (12.3) ] . QUVIVIQ is not recommended in patients with severe hepatic impairment (Child-Pugh score ≥ 10) [see Use in Specific Populations (8.6) ] ."],"drug_abuse_and_dependence":["9 DRUG ABUSE AND DEPENDENCE 9.1 Controlled Substance QUVIVIQ contains daridorexant, a Schedule IV controlled substance. 9.2 Abuse Drug abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. The abuse potential of daridorexant was evaluated in preclinical models, recreational sedative drug users, and insomnia subjects. In a human abuse potential study conducted in 63 recreational sedative drug users, the effect of single-dose administration of QUVIVIQ [50 mg, 100 mg (two times the maximum recommended dose), and 150 mg (three times the maximum recommended dose)], zolpidem (30 mg), suvorexant (150 mg), and placebo on subjective rating of \"drug liking\" was evaluated. At the dose of 50 mg, QUVIVIQ showed significantly lower \"drug liking\" ratings than zolpidem (30 mg) and suvorexant (150 mg), but significantly higher than placebo. At doses of 100 mg (two times the maximum recommended dose) and 150 mg (three times the maximum recommended dose), QUVIVIQ showed similar \"drug liking\" ratings to zolpidem (30 mg) and suvorexant (150 mg). In placebo-controlled Phase 3 clinical studies in which 1232 subjects with insomnia were treated with QUVIVIQ for up to 12 months, there were no reports indicative of abuse liability. Because individuals with a history of abuse of or addiction to alcohol or other drugs may be at increased risk for abuse of or addiction to QUVIVIQ, follow such patients carefully. 9.3 Dependence Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms upon abrupt treatment discontinuation or a significant dose reduction of a drug. In animal studies and clinical trials evaluating physical dependence, chronic administration of daridorexant did not produce withdrawal signs or symptoms upon drug discontinuation. This suggests that daridorexant does not produce physical dependence."],"spl_product_data_elements":["QUVIVIQ Daridorexant daridorexant daridorexant Mannitol MICROCRYSTALLINE CELLULOSE 101 Povidone K30 WATER Silicon dioxide Magnesium stearate MICROCRYSTALLINE CELLULOSE 102 HYPROMELLOSE, UNSPECIFIED GLYCERIN Talc Titanium dioxide FERRIC OXIDE RED FERROSOFERRIC OXIDE Light purple arc-triangle 25;i QUVIVIQ Daridorexant daridorexant daridorexant Mannitol MICROCRYSTALLINE CELLULOSE 101 Povidone K30 WATER Silicon dioxide Magnesium stearate MICROCRYSTALLINE CELLULOSE 102 HYPROMELLOSE, UNSPECIFIED GLYCERIN Talc Titanium dioxide FERRIC OXIDE RED FERROSOFERRIC OXIDE FERRIC OXIDE YELLOW Light orange arc-triangle 50;i"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS QUVIVIQ (daridorexant) tablets are available as: 25 mg: light purple, arc-triangle shaped, film-coated tablet debossed with \"25\" on one side and \"i\" (Idorsia logo) on the other side, containing 25 mg daridorexant. 50 mg: light orange, arc-triangle shaped, film-coated tablet debossed with \"50\" on one side and \"i\" (Idorsia logo) on the other side, containing 50 mg daridorexant. Tablets: 25 mg, 50 mg. ( 3 )"],"recent_major_changes_table":["
Contraindications (4)10/2023
Warnings and Precautions (5.5)9/2024
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Pregnancy Exposure Registry There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to QUVIVIQ during pregnancy. Pregnant women exposed to QUVIVIQ and healthcare providers are encouraged to call Idorsia Pharmaceuticals Ltd at 1-833-400-9611. Risk Summary There are no available data on QUVIVIQ use in pregnant women to evaluate for drug-associated risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of daridorexant to pregnant rats and rabbits during the period of organogenesis did not cause fetal toxicity or malformation at doses up to 8 and 10 times the maximum recommended human dose (MRHD) of 50 mg, respectively, based on AUC. Oral administration of daridorexant to pregnant and lactating rats did not cause any maternal or developmental toxicity at doses up to 9 times the MRHD, based on AUC (see Data ) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Daridorexant was administered orally to pregnant rats during the period of organogenesis at doses of 30, 100, and 300 mg/kg/day, which are approximately 1, 3, and 8 times the MRHD of 50 mg, respectively, based on AUC. Daridorexant did not cause any maternal or embryofetal toxicities or fetal malformation at doses up to 300 mg/kg/day. The NOAEL for maternal and fetal toxicity is 300 mg/kg/day, which is approximately 8 times the MRHD of 50 mg, based on AUC. Daridorexant was administered orally to pregnant rabbits during the period of organogenesis at doses of 30, 60, and 120 mg/kg/day, which are approximately 3, 4, and 10 times the MRHD of 50 mg, respectively, based on AUC. Daridorexant did not cause any fetal toxicity or malformation at doses up to 120 mg/kg/day. Daridorexant caused maternal toxicities of decreased weight gain and food consumption at the dose of 120 mg/kg/day. The NOAELs for maternal and fetal toxicity are 60 and 120 mg/kg/day, respectively, which are approximately 4 and 10 times the MRHD of 50 mg, respectively, based on AUC. Daridorexant was administered orally to pregnant rats during gestation and lactation at doses of 50, 100, and 300 mg/kg/day, which are approximately 1, 3, and 9 times the MRHD of 50 mg, respectively, based on AUC. Daridorexant did not cause any maternal or developmental toxicities at doses up to 300 mg/kg/day. The NOAEL for maternal and developmental toxicity is 300 mg/kg/day, which is approximately 9 times the MRHD of 50 mg, based on AUC. 8.2 Lactation Risk Summary Daridorexant is present in human breast milk in low amounts. In a clinical lactation study, daridorexant was detected in human milk at a mean daily infant dose of 0.0016 mg/kg, with a relative infant dose of <1% the maternal weight-adjusted dose (see Data ). There are no data on the effects of daridorexant on the breastfed infant or its effects on milk production. Infants exposed to QUVIVIQ through breastmilk should be monitored for excessive sedation. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for QUVIVIQ and any potential adverse effects on the breastfed infant from QUVIVIQ or from the underlying maternal condition. Data A lactation study in 10 healthy adult lactating women evaluated the concentrations of daridorexant in plasma and breast milk following a single dose of 50 mg daridorexant. The calculated mean daily infant dose is 0.0016 mg/kg based on an assumed infant body weight of 6 kg, and the relative infant dose is 0.22% of the maternal weight-adjusted dose. Approximately 87% of the total amount of daridorexant present in milk was detected by 24 hours after administration. The amount of daridorexant present in breast milk at steady state is expected to be similar to that after a single dose. 8.4 Pediatric Use The safety and effectiveness of QUVIVIQ have not been established in pediatric patients. 8.5 Geriatric Use No dose adjustment is required in patients over the age of 65 years. Of the total number of subjects in the clinical studies of QUVIVIQ with insomnia (N = 1854), approximately 39% (N = 727) were ≥ 65 years and 5.9% (N = 110) were ≥ 75 years. The likelihood of somnolence and fatigue increased with patient age. Because QUVIVIQ can increase somnolence and drowsiness, patients, particularly the elderly, are at higher risk of falls [see Warnings and Precautions (5.1) ] . 8.6 Hepatic Impairment QUVIVIQ has not been studied in patients with severe hepatic impairment (Child-Pugh score ≥ 10). Use in this population is not recommended [see Clinical Pharmacology (12.3) ] . Reduce the dose of QUVIVIQ in patients with moderate hepatic impairment (Child-Pugh score 7–9) [see Dosage and Administration (2.3) ] . Moderate hepatic impairment may increase daridorexant systemic exposure to a clinically relevant extent [see Clinical Pharmacology (12.3) ] , which may increase the frequency or severity of adverse reactions. 8.7 Patients with Compromised Respiratory Function Obstructive Sleep Apnea The respiratory depressant effect of QUVIVIQ was evaluated after one night and after five consecutive nights of treatment with QUVIVIQ 50 mg in a randomized, placebo-controlled, two-period crossover study in 25 patients with mild to moderate OSA (apnea-hypopnea index [AHI] 5 to 30 events per hour of sleep) not using CPAP. Following once-daily dosing of 50 mg in the evening, the mean treatment difference (daridorexant – placebo) on Day 5 for AHI was 0.74 (90% CI, -1.43 to 2.92). QUVIVIQ was also evaluated after 5 consecutive nights of treatment with QUVIVIQ 50 mg in a randomized, placebo-controlled, double-blind, two-period crossover study in 16 patients with severe OSA (apnea-hypopnea index ≥ 30 events per hour of sleep; studied range 30.8–82.2 events per hour) not using CPAP. Following once daily dosing of 50 mg in the evening, the mean treatment difference (daridorexant – placebo) on Day 5 for AHI was -3.74 (90% CI, -11.71 to 4.23). Due to study limitations, including the short duration of the studies, clinically meaningful respiratory effects of QUVIVIQ in OSA cannot be excluded, including for long-term treatment [see Warnings and Precautions (5.5) ] . Chronic Obstructive Pulmonary Disease The respiratory depressant effect of QUVIVIQ was evaluated after one night and after five consecutive nights of treatment with QUVIVIQ 50 mg in a randomized, placebo-controlled, two-period crossover study in 25 patients with moderate COPD (FEV 1 /FVC ratio ≤ 70% and 40% ≤ FEV 1 < 80% of predicted). Following once-daily dosing of 50 mg in the evening, the mean SpO 2 treatment difference (daridorexant – placebo) on Day 5 was 0.18% (90% CI, -0.21 to 0.57). QUVIVIQ has not been studied in patients with mild (FEV 1 ≥ 80% predicted) or severe COPD (FEV 1 < 40% of predicted). Clinically meaningful respiratory effects of QUVIVIQ in patients with compromised respiratory function cannot be excluded [see Warnings and Precautions (5.5) ] ."],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology In dogs, daily oral administration of daridorexant at ≥ 30 mg/kg/day resulted in behavior characteristic of cataplexy when presented with positive stimulation. The no-observed-effect level (NOEL) for cataplexy is 20 mg/kg/day, which is approximately 3 times the MRHD of 50 mg, based on C max and AUC."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 25 mg Tablet Bottle Carton NDC 80491-7825-3 QUVIVIQ ® (daridorexant) tablets 25 mg CIV Rx only For oral use 30 tablets Dispense the accompanying Medication Guide to each patient. idorsia PRINCIPAL DISPLAY PANEL - 25 mg Tablet Bottle Carton","PRINCIPAL DISPLAY PANEL - 50 mg Tablet Bottle Carton NDC 80491-7850-3 QUVIVIQ ® (daridorexant) tablets 50 mg CIV Rx only For oral use 30 tablets Dispense the accompanying Medication Guide to each patient. idorsia PRINCIPAL DISPLAY PANEL - 50 mg Tablet Bottle Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Daridorexant did not increase the incidence of tumors in rats treated for 2 years at oral doses of 15, 50, and 150 mg/kg/day. The high dose of 150 mg/kg/day is approximately 4 times the MRHD of 50 mg, based on AUC. Daridorexant did not increase the incidence of tumors in Tg.rasH2 mice treated for 26 weeks at oral doses of 100, 300, and 1000 mg/kg/day in males or 100, 200, and 1000 mg/kg/day in females. Mutagenesis Daridorexant was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay or in the in vitro mammalian chromosome aberration assay in human lymphocytes and was not clastogenic in the in vivo rat micronucleus assay. Impairment of Fertility Daridorexant was orally administered to female rats at doses of 30, 100, and 300 mg/kg/day prior to and throughout mating and continuing to gestation Day 6. These doses are approximately 0.5, 3, and 9 times the MRHD of 50 mg, based on AUC. Daridorexant increased pre-implantation loss and decreased implantation sites without affecting mating or fertility at 300 mg/kg/day. The NOAEL for female fertility is 100 mg/kg/day, which is approximately 3 times the MRHD of 50 mg, based on AUC. Daridorexant did not affect fertility when orally administered to male rats at doses of 50, 150, and 450 mg/kg/day prior to and throughout mating. These doses are approximately 1, 3, and 7 times the MRHD of 50 mg, based on AUC."]},"tags":[{"label":"Orexin Receptor Antagonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Orexin receptor type 1","category":"target"},{"label":"HCRTR1","category":"gene"},{"label":"HCRTR2","category":"gene"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Insomnia","category":"indication"},{"label":"Idorsia","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"451 reports"},{"date":"","signal":"INSOMNIA","source":"FDA FAERS","actionTaken":"282 reports"},{"date":"","signal":"NIGHTMARE","source":"FDA FAERS","actionTaken":"270 reports"},{"date":"","signal":"SOMNOLENCE","source":"FDA FAERS","actionTaken":"160 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"151 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"149 reports"},{"date":"","signal":"PRODUCT AVAILABILITY ISSUE","source":"FDA FAERS","actionTaken":"147 reports"},{"date":"","signal":"ABNORMAL DREAMS","source":"FDA FAERS","actionTaken":"126 reports"},{"date":"","signal":"INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION","source":"FDA FAERS","actionTaken":"120 reports"},{"date":"","signal":"FEELING ABNORMAL","source":"FDA FAERS","actionTaken":"118 reports"}],"drugInteractions":[{"drug":"Strong CYP3A4 inhibitors","severity":"major","mechanism":"Increases exposure to daridorexant","management":"Avoid concomitant use","clinicalEffect":"May increase the risk of QUVIVIQ adverse reactions"},{"drug":"Moderate CYP3A4 inhibitors","severity":"moderate","mechanism":"Increases exposure to daridorexant","management":"Maximum recommended dose is 25 mg","clinicalEffect":"May increase the risk of QUVIVIQ adverse reactions"},{"drug":"Strong or Moderate CYP3A4 inducers","severity":"major","mechanism":"Decreases exposure to daridorexant","management":"Avoid concomitant use","clinicalEffect":"May reduce the efficacy of QUVIVIQ"},{"drug":"Alcohol and Other CNS Depressants","severity":"major","mechanism":"Additive impairment of psychomotor performance and risk of CNS depression","management":"Avoid alcohol consumption with QUVIVIQ; use with caution in patients receiving CNS depressants; consider dose adjustment of QUVIVIQ and/or the CNS depressant(s) if used concomitantly","clinicalEffect":"Increased risk of CNS depression"},{"drug":"CYP3A4 Substrates","severity":"moderate","mechanism":"Increases exposure to CYP3A4 substrate","management":"Use with caution in patients receiving CYP3A4 substrates with narrow therapeutic index","clinicalEffect":"May affect the therapeutic effect of CYP3A4 substrates"},{"drug":"P-gp Substrates","severity":"moderate","mechanism":"Increases exposure to P-gp substrate","management":"Use with caution in patients receiving P-gp substrates with a narrow therapeutic index","clinicalEffect":"May affect the therapeutic effect of P-gp substrates"}],"commonSideEffects":[{"effect":"Headache","drugRate":"6.1%","severity":"common","_validated":true},{"effect":"Somnolence or fatigue","drugRate":"6.1%","severity":"common","_validated":true},{"effect":"Dizziness","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Nausea","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Sleep paralysis","drugRate":"0.5%","severity":"mild","_validated":true},{"effect":"Hypnagogic and hypnopompic hallucinations","drugRate":"0.6%","severity":"mild","_validated":true},{"effect":"Sedation","drugRate":"reported","severity":"unknown"},{"effect":"Lethargy","drugRate":"reported","severity":"unknown"},{"effect":"Hypersomnia","drugRate":"reported","severity":"unknown"},{"effect":"Vertigo","drugRate":"reported","severity":"unknown"},{"effect":"Labyrinthitis","drugRate":"reported","severity":"unknown"},{"effect":"Vomiting","drugRate":"reported","severity":"unknown"},{"effect":"Migraine","drugRate":"reported","severity":"unknown"},{"effect":"Head discomfort","drugRate":"reported","severity":"unknown"}],"contraindications":["QUVIVIQ is contraindicated in patients with narcolepsy.","QUVIVIQ is contraindicated in patients with a history of hypersensitivity to daridorexant or any components of QUVIVIQ."],"specialPopulations":{"Lactation":"There are no data on the presence of daridorexant in human milk, the effects on the breastfed infant, or the effects on milk production. Infants exposed to QUVIVIQ through breastmilk should be monitored for excessive sedation.","Pregnancy":"There are no available data on QUVIVIQ use in pregnant women to evaluate for drug-associated risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of daridorexant to pregnant rats and rabbits during the period of organogenesis did not cause fetal toxicity or malformation at doses up to and 10 times the maximum recommended human dose (MRHD) of 50 mg, respectively, based on AUC. Infants exposed to QUVIVIQ through breastmilk should be monitored for excessive sedation.","Geriatric use":"No dose adjustment is required in patients over the age of 65 years. The likelihood of somnolence and fatigue increased with patient age. Because QUVIVIQ can increase somnolence and drowsiness, patients, particularly the elderly, are at higher risk of falls.","Paediatric use":"The safety and effectiveness of QUVIVIQ have not been established in pediatric patients."}},"trials":[],"aliases":[],"company":"Idorsia","patents":[{"applNo":"N214985","source":"FDA Orange Book","status":"Active","expires":"Jun 12, 2033","useCode":"U-620","territory":"US","drugProduct":true,"patentNumber":"9732075","drugSubstance":true},{"applNo":"N214985","source":"FDA Orange Book","status":"Active","expires":"Dec 2, 2034","useCode":"U-620","territory":"US","drugProduct":false,"patentNumber":"10023560","drugSubstance":false},{"applNo":"N214985","source":"FDA Orange Book","status":"Active","expires":"Dec 2, 2034","useCode":"","territory":"US","drugProduct":true,"patentNumber":"9790208","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DARIDOREXANT","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:38:53.643480+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:38:49.160029+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:39:00.524910+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:38:53.664856+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:38:47.680436+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DARIDOREXANT","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:39:01.273680+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:38:46.671260+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:38:46.671306+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:38:46.671316+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:39:02.782521+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Orexin receptor 2 antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:39:01.850636+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:39:39.197970+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650216/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:39:01.747099+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:39:09.051706+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA214985","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:38:46.671322+00:00"}},"allNames":"quviviq","offLabel":[],"synonyms":["daridorexant","quviviq","daridorexant hydrochloride","ACT-541468","nemorexant"],"timeline":[{"date":"2022-01-01","type":"positive","source":"DrugCentral","milestone":"FDA approval (Idorsia Pharmaceuticals Ltd)"},{"date":"2022-04-29","type":"positive","source":"DrugCentral","milestone":"EMA approval (Idorsia Pharmaceuticals Deutschland Gmbh)"},{"date":"2027-04-07","type":"negative","source":"FDA Orange Book","milestone":"New Chemical Entity exclusivity expires"},{"date":"2027-09-30","type":"negative","source":"FDA Orange Book","milestone":"M-200 exclusivity expires"},{"date":"2033-06-12","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 9732075 expires"},{"date":"2034-12-02","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 9790208 expires"}],"aiSummary":"Quviviq (daridorexant) is a small molecule orexin receptor antagonist developed by IDORSIA PHARMACEUTICALS LTD and currently owned by Idorsia. It targets the orexin receptor type 1 to treat insomnia. Quviviq was FDA-approved in 2022 and is a patented medication with no generic manufacturers. Key safety considerations include its mechanism of action, which may affect sleep-wake cycles and other physiological processes. As a relatively new medication, long-term effects and potential interactions are still being studied.","approvals":[{"date":"2022-01-01","orphan":false,"company":"IDORSIA PHARMACEUTICALS LTD","regulator":"FDA"},{"date":"2022-04-29","orphan":false,"company":"IDORSIA PHARMACEUTICALS DEUTSCHLAND GMBH","regulator":"EMA"}],"brandName":"Quviviq","ecosystem":[{"indication":"Insomnia","otherDrugs":[{"name":"amobarbital","slug":"amobarbital","company":""},{"name":"choline","slug":"choline","company":""},{"name":"diphenhydramine","slug":"diphenhydramine","company":"Mcneil Cons"},{"name":"doxepin","slug":"doxepin","company":""}],"globalPrevalence":750000000}],"mechanism":{"target":"Orexin receptor type 1","novelty":"Follow-on","targets":[{"gene":"HCRTR1","source":"DrugCentral","target":"Orexin receptor type 1","protein":"Orexin receptor type 1"},{"gene":"HCRTR2","source":"DrugCentral","target":"Orexin receptor type 2","protein":"Orexin receptor type 2"}],"moaClass":"Orexin Receptor Antagonists","modality":"Small Molecule","drugClass":"Orexin Receptor Antagonist [EPC]","explanation":"The mechanism of action of daridorexant in the treatment of insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system plays role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin and orexin to receptors OX1R and OX2R is thought to suppress wake drive.","oneSentence":"Quviviq works by blocking the action of orexin, a neurotransmitter that helps regulate sleep-wake cycles.","technicalDetail":"Quviviq selectively antagonizes the orexin receptor type 1 (OX1R), a subtype of orexin receptor, to modulate the orexin system and promote sleep."},"commercial":{"launchDate":"2022","_launchSource":"DrugCentral (FDA 2022-01-01, IDORSIA PHARMACEUTICALS LTD)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5493","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DARIDOREXANT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DARIDOREXANT","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T10:25:22.237106","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:39:40.266279+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"lemborexant","drugSlug":"lemborexant","fdaApproval":"2019-12-20","patentExpiry":"Sep 20, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"suvorexant","drugSlug":"suvorexant","fdaApproval":"2014-08-13","patentExpiry":"Nov 20, 2029","patentStatus":"Patent protected","relationship":"same-target"}],"exclusivity":[{"code":"M-200","date":"Sep 30, 2027"},{"code":"M-310","date":"Sep 30, 2027"},{"code":"NCE","date":"Apr 7, 2027"},{"code":"M-200","date":"Sep 30, 2027"},{"code":"M-310","date":"Sep 30, 2027"},{"code":"NCE","date":"Apr 7, 2027"}],"genericName":"daridorexant","indications":{"approved":[{"name":"Insomnia","source":"DrugCentral","snomedId":193462001,"regulator":"FDA","eligibility":"adult patients","usPrevalence":70000000,"globalPrevalence":750000000,"prevalenceMethod":"curated","prevalenceSource":"Sleep Medicine Reviews, 2023"}],"offLabel":[],"pipeline":[]},"currentOwner":"Idorsia","drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"lemborexant","brandName":"lemborexant","genericName":"lemborexant","approvalYear":"2019","relationship":"same-target"},{"drugId":"suvorexant","brandName":"suvorexant","genericName":"suvorexant","approvalYear":"2014","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07267559","phase":"PHASE4","title":"Dual Orexin Antagonism and Emotion and Affective Processing Study","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-10-01","conditions":["Learning","Cognitive Functioning","Emotional Processing"],"enrollment":62,"completionDate":"2026-10-01"},{"nctId":"NCT07136415","phase":"PHASE4","title":"Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-02-13","conditions":["Menopausal Women","Insomnia"],"enrollment":1000,"completionDate":"2031-02"},{"nctId":"NCT05423717","phase":"PHASE2","title":"Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2022-09-06","conditions":["Insomnia"],"enrollment":166,"completionDate":"2026-02-05"},{"nctId":"NCT07028697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder","status":"COMPLETED","sponsor":"Nxera Pharma Korea Co., Ltd.","startDate":"2024-12-04","conditions":["Insomnia Disorder"],"enrollment":164,"completionDate":"2025-10-21"},{"nctId":"NCT07328594","phase":"PHASE4","title":"Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking","status":"NOT_YET_RECRUITING","sponsor":"Legacy Health System","startDate":"2026-02-10","conditions":["Smoking","Nicotine","Tobacco","Addiction","Substance Use Disorders","Insomnia","Sleep"],"enrollment":44,"completionDate":"2027-09-30"},{"nctId":"NCT07217912","phase":"PHASE2","title":"Daridorexant to Prevent Post-cardiotomy Delirium","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2025-10-14","conditions":["Postoperative Cognitive Decline","Postoperative Delirium"],"enrollment":80,"completionDate":"2027-11-01"},{"nctId":"NCT07213349","phase":"PHASE2","title":"Daridorexant for Alzheimer Disease Prevention","status":"RECRUITING","sponsor":"Douglas Mental Health University Institute","startDate":"2025-10-14","conditions":["Alzheimer Disease (AD)"],"enrollment":240,"completionDate":"2029-12"},{"nctId":"NCT06498128","phase":"","title":"Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®","status":"RECRUITING","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2024-11-21","conditions":["Insomnia"],"enrollment":785,"completionDate":"2033-03"},{"nctId":"NCT05948540","phase":"PHASE2","title":"Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant","status":"RECRUITING","sponsor":"Global Coalition for Adaptive Research","startDate":"2023-11-02","conditions":["Post Traumatic Stress Disorder"],"enrollment":200,"completionDate":"2026-09"},{"nctId":"NCT05422612","phase":"PHASE2","title":"Department of Defense PTSD Adaptive Platform Trial - Master Protocol","status":"RECRUITING","sponsor":"Global Coalition for Adaptive Research","startDate":"2023-11-02","conditions":["Post Traumatic Stress Disorder"],"enrollment":800,"completionDate":"2026-09"},{"nctId":"NCT07132086","phase":"","title":"Prospective Observational Study on the Effectiveness of Daridorexant in Chronic Insomnia in a Real-World Setting","status":"COMPLETED","sponsor":"Azienda Ospedaliero, Universitaria Pisana","startDate":"2023-10-01","conditions":["Insomnia Chronic"],"enrollment":31,"completionDate":"2025-06-30"},{"nctId":"NCT06393504","phase":"","title":"Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2023-11-30","conditions":["Insomnia Disorder"],"enrollment":2095,"completionDate":"2028-04"},{"nctId":"NCT06630390","phase":"PHASE2","title":"Daridorexant to Prevent Delirium After Heart Surgery","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2024-11-11","conditions":["POSTOPERATIVE DELIRIUM","POSTOPERATIVE COGNITIVE DECLINE"],"enrollment":11,"completionDate":"2025-02-16"},{"nctId":"NCT05597020","phase":"PHASE4","title":"A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2023-02-16","conditions":["Insomnia Disorder","Nocturia"],"enrollment":60,"completionDate":"2024-04-18"},{"nctId":"NCT06311864","phase":"","title":"Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia with Daridorexant in Canada","status":"ENROLLING_BY_INVITATION","sponsor":"PeriPharm","startDate":"2024-06-20","conditions":["Insomnia"],"enrollment":100,"completionDate":"2025-10"},{"nctId":"NCT06010693","phase":"PHASE3","title":"A Study of Daridorexant in Chinese Patients With Insomnia Disorder","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2023-08-28","conditions":["Insomnia Disorder"],"enrollment":206,"completionDate":"2024-05-10"},{"nctId":"NCT05924425","phase":"PHASE4","title":"Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2024-03-13","conditions":["Alzheimer Disease","Insomnia Disorder","Sleep"],"enrollment":62,"completionDate":"2027-03-13"},{"nctId":"NCT06326723","phase":"PHASE1","title":"Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2023-09-04","conditions":["Healthy Volunteer"],"enrollment":32,"completionDate":"2024-02-05"},{"nctId":"NCT05877222","phase":"PHASE1","title":"A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2023-06-23","conditions":["Healthy"],"enrollment":38,"completionDate":"2023-08-04"},{"nctId":"NCT05702177","phase":"PHASE1","title":"A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2023-01-05","conditions":["Healthy"],"enrollment":36,"completionDate":"2023-04-25"},{"nctId":"NCT05632393","phase":"PHASE1","title":"A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2023-01-16","conditions":["Healthy"],"enrollment":10,"completionDate":"2023-04-30"},{"nctId":"NCT05458193","phase":"PHASE1","title":"A Study to Investigate the Effects of Daridorexant on Nighttime Breathing in Patients With Shallow or Paused Breath During Sleep","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2022-08-17","conditions":["Obstructive Sleep Apnea of Adult"],"enrollment":20,"completionDate":"2023-02-28"},{"nctId":"NCT05480475","phase":"PHASE1","title":"A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Dabigatran and Rosuvastatin in Healthy Male Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2022-09-03","conditions":["Healthy"],"enrollment":24,"completionDate":"2022-09-17"},{"nctId":"NCT05480488","phase":"PHASE1","title":"A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Midazolam and Warfarin in Healthy Male Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2022-08-23","conditions":["Healthy"],"enrollment":18,"completionDate":"2022-10-06"},{"nctId":"NCT03575104","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","isPivotal":true,"startDate":"2018-05-29","conditions":["Insomnia Disorder"],"enrollment":924,"completionDate":"2020-05-14"},{"nctId":"NCT03545191","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","isPivotal":true,"startDate":"2018-06-04","conditions":["Insomnia Disorder"],"enrollment":930,"completionDate":"2020-02-25"},{"nctId":"NCT03679884","phase":"PHASE3","title":"Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","isPivotal":true,"startDate":"2018-10-09","conditions":["Insomnia Disorder"],"enrollment":804,"completionDate":"2021-02-22"},{"nctId":"NCT04250506","phase":"PHASE1","title":"A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2020-02-28","conditions":["Healthy"],"enrollment":36,"completionDate":"2020-07-22"},{"nctId":"NCT04390334","phase":"PHASE1","title":"A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2020-05-13","conditions":["Healthy"],"enrollment":24,"completionDate":"2020-06-26"},{"nctId":"NCT04024332","phase":"PHASE1","title":"Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2019-09-24","conditions":["Renal Insufficiency","Healthy"],"enrollment":16,"completionDate":"2020-08-14"},{"nctId":"NCT03713242","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2018-02-26","conditions":["Hepatic Impairment"],"enrollment":32,"completionDate":"2020-02-27"},{"nctId":"NCT02841709","phase":"PHASE2","title":"Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2016-11-28","conditions":["Insomnia Disorder"],"enrollment":58,"completionDate":"2017-06-29"},{"nctId":"NCT02839200","phase":"PHASE2","title":"Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2016-10-04","conditions":["Insomnia Disorder"],"enrollment":360,"completionDate":"2017-06-20"},{"nctId":"NCT03765294","phase":"PHASE1","title":"A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2019-03-14","conditions":["Obstructive Sleep Apnea"],"enrollment":28,"completionDate":"2019-11-05"},{"nctId":"NCT03892902","phase":"PHASE1","title":"A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2019-03-25","conditions":["Healthy"],"enrollment":56,"completionDate":"2019-10-10"},{"nctId":"NCT03907215","phase":"PHASE1","title":"A Clinical Study to Examine the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2019-04-09","conditions":["Healthy"],"enrollment":24,"completionDate":"2019-06-26"},{"nctId":"NCT03646864","phase":"PHASE1","title":"A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2018-11-15","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":28,"completionDate":"2019-09-19"},{"nctId":"NCT03657355","phase":"PHASE1","title":"Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2018-09-07","conditions":["Healthy Recreational Drug Users"],"enrollment":63,"completionDate":"2019-08-08"},{"nctId":"NCT03799978","phase":"PHASE1","title":"A Clinical Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2019-03-09","conditions":["Healthy"],"enrollment":20,"completionDate":"2019-03-18"},{"nctId":"NCT03609775","phase":"PHASE1","title":"A Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2018-08-28","conditions":["Healthy"],"enrollment":22,"completionDate":"2018-10-09"},{"nctId":"NCT02571855","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2015-10-01","conditions":["Healthy Subjects"],"enrollment":85,"completionDate":"2016-02-01"},{"nctId":"NCT03017495","phase":"PHASE1","title":"A Clinical Study to Investigate the Potential Interactions Between Food and ACT-541468 and Between ACT-541468 and Midazolam","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2017-01-01","conditions":["Healthy Subjects"],"enrollment":20,"completionDate":"2017-02-01"},{"nctId":"NCT03101189","phase":"PHASE1","title":"A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2017-03-15","conditions":["Healthy Subjects"],"enrollment":40,"completionDate":"2017-04-26"},{"nctId":"NCT02919319","phase":"PHASE1","title":"A Single Ascending Dose Study of ACT-541468 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2015-02-01","conditions":["Healthy Subjects"],"enrollment":40,"completionDate":"2015-05-01"},{"nctId":"NCT02526888","phase":"PHASE1","title":"Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2015-09-01","conditions":["Healthy Subjects"],"enrollment":14,"completionDate":"2015-11-01"},{"nctId":"NCT03339752","phase":"PHASE1","title":"A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2017-10-30","conditions":["Healthy Subjects"],"enrollment":20,"completionDate":"2017-12-02"}],"_emaApprovals":[{"date":"2022-04-29","status":"Authorised","company":"IDORSIA PHARMACEUTICALS DEUTSCHLAND GMBH"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT03545191","NCT03575104","NCT03679884"],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET, FILM COATED","route":"ORAL","productName":"QUVIVIQ"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"358453","NDDF":"018928","UNII":"LMQ24G57E9","VANDF":"4041355","INN_ID":"10679","RXNORM":"2591496","UMLSCUI":"C5227711","chemblId":"CHEMBL4650216","ChEMBL_ID":"CHEMBL4297590","KEGG_DRUG":"D11886","DRUGBANK_ID":"DB15031","PDB_CHEM_ID":"NS2","PUBCHEM_CID":"91801202","IUPHAR_LIGAND_ID":"11648","SECONDARY_CAS_RN":"1792993-84-0","MESH_SUPPLEMENTAL_RECORD_UI":"C000634383"},"formularyStatus":[],"originalProduct":{"form":"TABLET, FILM COATED","route":"ORAL","company":"Idorsia Pharmaceuticals Ltd","brandName":"QUVIVIQ","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2022-","companyName":"Idorsia Pharmaceuticals Ltd","relationship":"Original Developer"},{"period":"present","companyName":"Idorsia","relationship":"Current Owner"},{"period":"2022","companyName":"Idorsia Pharmaceuticals Deutschland Gmbh","relationship":"EMA Licensee"}],"publicationCount":157,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"originalDeveloper":"Idorsia Pharmaceuticals Ltd","recentPublications":[{"date":"2026 Mar 25","pmid":"41879869","title":"Unveiling the binding mechanism of orexin 2 receptor antagonists with computational chemistry.","journal":"Physical chemistry chemical physics : PCCP"},{"date":"2026 Mar 18","pmid":"41837408","title":"What place does daridorexant have in the treatment of Binge-Eating Disorder?","journal":"Expert review of neurotherapeutics"},{"date":"2026 Mar 15","pmid":"41817674","title":"Daridorexant: exploring its role in the treatment of insomnia disorder.","journal":"Expert review of neurotherapeutics"},{"date":"2026 Feb 13","pmid":"41719767","title":"Real-world findings of daridorexant in chronic insomnia: A pilot study on subjective and actigraphic sleep parameters.","journal":"Sleep medicine"},{"date":"2026 Feb 17","pmid":"41700897","title":"Clinical toxicity of daridorexant: a retrospective analysis of poison centre data.","journal":"Clinical toxicology (Philadelphia, Pa.)"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Idorsia","companyId":"idorsia","modality":"Small molecule","firstApprovalDate":"2022","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-01-01T00:00:00.000Z","mah":"IDORSIA PHARMACEUTICALS LTD","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-11-08T00:00:00.000Z","mah":"IDORSIA","brand_name_local":null,"application_number":"NDA214985"},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":9,"withResults":3},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:39:40.266279+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}